title: Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan.
abstract: To evaluate the role of oxidative stress and aflatoxin exposure on risk of hepatocellular carcinoma (HCC), a case-control study nested within a large community-based cohort was conducted in Taiwan. Baseline urine samples, collected from a total of 74 incident HCC cases and 290 matched controls, were used to determine by enzyme-linked immunosorbent assays the level of urinary 15-F(2t)-isoprostane (15-F(2t)-IsoP), a biomarker of lipid peroxidation. These samples had been previously analyzed for urinary aflatoxin B(1) (AFB(1)) metabolites and 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG). Pearson partial correlation coefficient analysis showed that urinary AFB(1) metabolites and 8-oxodG were significantly associated with the level of urinary 15-F(2t)-IsoP. After adjustment for potential confounding factors in a conditional logistic regression model, urinary 15-F(2t)-IsoP was significantly associated with risk of HCC [above versus below the mean odds ratio (OR) = 2.53, 95% confidence interval (CI) = 1.30-4.93]. Moreover, when compared with subjects in the lowest tertile of 15-F(2t)-IsoP, there was a trend of increasing risk of HCC (P(trend) = 0.0008), with adjusted ORs (95% CIs) of 3.87 (1.32-11.38) and 6.27 (2.17-18.13) for the second and third tertile, respectively. In addition, the combination of urinary 15-F(2t)-IsoP above the mean and chronic hepatitis B virus (HBV) infection resulted in an OR of 19.01 (95% CI = 6.67-54.17) compared with those with low urinary 15-F(2t)-IsoP and without HBV infection. These results suggest that elevated levels of urinary 15-F(2t)-IsoP may be related to increasing level of aflatoxin exposure and are associated with an increased risk of HCC.
authors.affiliation: Department of Environmental Health Sciences, Mailman School of Public Health of Columbia University, New York, NY 10032, USA.
authors.forename: Hui-Chen
authors.initials: HC
authors.lastname: Wu
authors.forename: Qiao
authors.initials: Q
authors.lastname: Wang
authors.forename: Hwai-I
authors.initials: HI
authors.lastname: Yang
authors.forename: Habibul
authors.initials: H
authors.lastname: Ahsan
authors.forename: Wei-Yann
authors.initials: WY
authors.lastname: Tsai
authors.forename: Li-Yu
authors.initials: LY
authors.lastname: Wang
authors.forename: Shu-Yuan
authors.initials: SY
authors.lastname: Chen
authors.forename: Chien-Jen
authors.initials: CJ
authors.lastname: Chen
authors.forename: Regina M
authors.initials: RM
authors.lastname: Santella
mesh_terms: D016604:Aflatoxin B1 / Q000493:pharmacokinetics / Q000633:toxicity*; D015415:Biomarkers / Q000652:urine; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000401:mortality / Q000821:virology; D003644:Death Certificates; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000652:urine; D006509:Hepatitis B / Q000150:complications*; D006801:Humans; D007407:Interviews as Topic; D015227:Lipid Peroxidation; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000821:virology; D008403:Mass Screening; D016017:Odds Ratio; D012016:Reference Values; D012042:Registries; D013624:Taiwan / Q000453:epidemiology
chemical_list: D015415:Biomarkers; C075750:8-epi-prostaglandin F2alpha; D016604:Aflatoxin B1; D015237:Dinoprost